Logo image of TLGT

Teligent Inc (TLGT) Stock Fundamental Analysis

NASDAQ:TLGT - Nasdaq -

0.1735  -0.03 (-13.85%)

After market: 0.1717 0 (-1.04%)

Fundamental Rating

2

TLGT gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 193 industry peers in the Pharmaceuticals industry. TLGT has a bad profitability rating. Also its financial health evaluation is rather negative. TLGT does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year TLGT has reported negative net income.

1.2 Ratios

Industry RankSector Rank
ROA -101.27%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

Industry RankSector Rank
OM -296.25%
PM (TTM) -197.78%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

3

2. Health

2.1 Basic Checks

TLGT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

TLGT has an Altman-Z score of -6.66. This is a bad value and indicates that TLGT is not financially healthy and even has some risk of bankruptcy.
TLGT has a Debt/Equity ratio of -2.67. This is a healthy value indicating a solid balance between debt and equity.
Industry RankSector Rank
Debt/Equity -2.67
Debt/FCF N/A
Altman-Z -6.66
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

TLGT has a Current Ratio of 4.10. This indicates that TLGT is financially healthy and has no problem in meeting its short term obligations.
A Quick Ratio of 2.74 indicates that TLGT has no problem at all paying its short term obligations.
Industry RankSector Rank
Current Ratio 4.1
Quick Ratio 2.74

More info and screens

2

3. Growth

3.1 Past

TLGT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 27.02%, which is quite impressive.
Looking at the last year, TLGT shows a very negative growth in Revenue. The Revenue has decreased by -16.53% in the last year.
Measured over the past years, TLGT shows a small growth in Revenue. The Revenue has been growing by 0.47% on average per year.
EPS 1Y (TTM)27.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%90.91%
Revenue 1Y (TTM)-16.53%
Revenue growth 3Y-9.04%
Revenue growth 5Y0.47%
Sales Q2Q%-23.21%

3.2 Future

Based on estimates for the next years, TLGT will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.63% on average per year.
Based on estimates for the next years, TLGT will show a decrease in Revenue. The Revenue will decrease by -0.27% on average per year.
EPS Next Y131.61%
EPS Next 2Y65.35%
EPS Next 3Y24.17%
EPS Next 5Y17.63%
Revenue Next Year-16.85%
Revenue Next 2Y-16.02%
Revenue Next 3Y-0.47%
Revenue Next 5Y-0.27%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
TLGT Yearly Revenue VS EstimatesTLGT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
TLGT Yearly EPS VS EstimatesTLGT Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2 -2 4 -4 -6

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TLGT. In the last year negative earnings were reported.
With a Price/Forward Earnings ratio of 0.04, the valuation of TLGT can be described as very cheap.
The average S&P500 Price/Forward Earnings ratio is at 35.19. TLGT is valued rather cheaply when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 0.04
TLGT Price Earnings VS Forward Price EarningsTLGT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -0.85
TLGT Per share dataTLGT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 -6

4.3 Compensation for Growth

TLGT's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as TLGT's earnings are expected to grow with 24.17% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y65.35%
EPS Next 3Y24.17%

More info and screens

0

5. Dividend

5.1 Amount

TLGT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Teligent Inc

NASDAQ:TLGT (10/15/2021, 8:08:54 PM)

After market: 0.1717 0 (-1.04%)

0.1735

-0.03 (-13.85%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)N/A N/A
Earnings (Next)03-01 2022-03-01/dmh
Inst Owners12.88%
Inst Owner Change-1.18%
Ins Owners0.36%
Ins Owner Change0%
Market Cap16.10M
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 0.04
P/S 0.35
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA -0.85
EPS(TTM)-7.24
EYN/A
EPS(NY)4.7
Fwd EY2706.29%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.5
BVpS-0.47
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -101.27%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM -296.25%
PM (TTM) -197.78%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.51
Health
Industry RankSector Rank
Debt/Equity -2.67
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.1
Quick Ratio 2.74
Altman-Z -6.66
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)27.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%90.91%
EPS Next Y131.61%
EPS Next 2Y65.35%
EPS Next 3Y24.17%
EPS Next 5Y17.63%
Revenue 1Y (TTM)-16.53%
Revenue growth 3Y-9.04%
Revenue growth 5Y0.47%
Sales Q2Q%-23.21%
Revenue Next Year-16.85%
Revenue Next 2Y-16.02%
Revenue Next 3Y-0.47%
Revenue Next 5Y-0.27%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A